BGMS Bio Green Med Solution, Inc.
Wholesale-Durable Goods, NEC · Nasdaq · SEC CIK 1130166 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY69.4%
TTM EPS YoY75.3%
Revenue 3-yr CAGR55.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-156.1%
Net margin-114.5%
FCF margin—
EBITDA margin-155.7%
Returns
ROE-24.2%
ROA-21.3%
ROIC (approx.)-68.7%
Asset turnover0.19x
Leverage & solvency
Liabilities / assets10.9%
Debt / equity0.00x
Current ratio6.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.57x
Accruals ratio-9.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $454,000 | $336,000 | $743,000 | -$80,961 | $81,000 | — | — | $0 |
| R&D expense | — | — | — | -$47,000 | $5,000 | $68,000 | $822,000 | $880,000 |
| SG&A expense | $635,000 | $497,000 | $389,000 | $1.25M | $1.00M | $1.25M | $4.21M | $948,000 |
| Operating income | -$520,000 | -$418,000 | -$246,000 | -$1.08M | -$987,000 | -$1.25M | -$4.21M | -$1.83M |
| Pretax income | -$446,000 | -$396,000 | -$167,000 | $3.45M | -$983,000 | -$1.25M | -$4.21M | -$1.86M |
| Income tax | $3,000 | $9,000 | $30,000 | $5,000 | $0 | $2,000 | — | $1.19M |
| Net income | -$449,000 | -$405,000 | -$197,000 | -$611,000 | -$988,000 | -$1.32M | -$81,000 | -$3.05M |
| EBITDA | -$520,000 | -$418,000 | -$245,000 | -$1.08M | -$987,000 | — | — | -$1.83M |
| EPS (basic) | -0.07 | — | — | — | -1.31 | -0.98 | 0.00 | — |
| EPS (diluted) | -0.07 | — | — | — | -1.31 | -0.98 | 0.00 | — |
| Weighted avg. shares (diluted) | 6.62M | 5.60M | 5.46M | — | 1.91M | 1.36M | 365,231 | — |
| Banking | ||||||||
| Net interest income | $44,000 | $9,000 | $9,000 | $45,000 | $9,000 | $2,000 | $6,000 | $30,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $3.45M | $3.79M | $3.34M | $3.50M | $3.84M | $4.28M | $3.45M | $3.14M |
| Receivables | $974,000 | $1.07M | $1.19M | $1.26M | $725,000 | — | — | — |
| Inventory | $991,000 | $972,000 | $947,000 | $1.38M | $1.37M | — | — | — |
| Current assets | $5.58M | $5.97M | $5.62M | $6.26M | $6.44M | $4.38M | $3.71M | $3.67M |
| PP&E, net | $134,000 | $136,000 | $138,000 | $137,000 | $129,000 | $1,000 | $1,000 | $3,000 |
| Goodwill | $1.57M | $1.57M | $1.57M | $1.57M | $1.57M | — | — | — |
| Total assets | $7.48M | $7.85M | $7.56M | $8.19M | $8.16M | $4.40M | $3.73M | $4.09M |
| Current liabilities | $815,000 | $692,000 | $796,000 | $1.33M | $1.00M | $760,000 | $663,000 | $6.27M |
| Total liabilities | $817,000 | $694,000 | $804,000 | $1.34M | $1.06M | $770,000 | $672,000 | $6.27M |
| Shareholders' equity | $6.66M | $7.16M | $6.76M | $6.84M | $7.10M | $3.63M | $3.06M | -$2.17M |
| Shares outstanding | 6.62M | 6.62M | 5.52M | 5.40M | 3.50M | 1.58M | 207.34M | 36,913 |
| Cash flow statement | ||||||||
| Operating cash flow | -$287,000 | -$352,000 | -$278,000 | -$33,000 | -$434,000 | -$1.06M | -$3.25M | -$1.36M |
| Capital expenditure | $0 | $0 | $1,000 | — | — | — | — | — |
| Free cash flow | -$287,000 | -$352,000 | -$279,000 | — | — | — | — | — |
| Investing cash flow | $0 | $0 | -$1,000 | — | — | — | — | — |
| Financing cash flow | -$20,000 | $773,000 | $105,000 | -$259,000 | -$3,000 | $1.88M | $3.65M | $1.61M |
| Depreciation & amortization | $0 | $0 | $1,000 | $4,000 | $0 | — | — | $1,000 |
| Stock-based compensation | $0 | $1,000 | $1,000 | $655,000 | $6,000 | $7,000 | $1.67M | $93,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.